Inhibition of Streptococcus pyogenes growth by native Australian plants: New approaches towards the management of impetigo, pharyngitis and rheumatic heart disease

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Jay Lee, Cameron
Henry Wright, Mitchell
Jean Arnold, Megan Sarah
Carlson Greene, Anthony
Edwin Cock, Ian
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2016
Size
File type(s)
Location
Abstract

Introduction: Streptococcus pyogenes can cause a variety of diseases including streptococcal pharyngitis, impetigo and rheumatic heart disease, dependant on which tissue it infects. Many Australian plants have documented therapeutic properties as general antiseptics, but are yet to be tested for the ability to inhibit S. pyogenes growth. Methods: Solvent extracts were prepared using Australian plants with documented ethnobotanical usage to treat bacterial infections, or published antibacterial activity. The extracts were investigated by disc diffusion assay for the ability to inhibit the growth of a clinical strain of S. pyogenes. Their MIC values were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: S. pyogenes growth was inhibited by 24 of the 34 extracts tested. The Eucalyptus spp. extracts were particularly potent. MIC values of 341 and 88 μg/ mL were determined for the aqueous and methanolic E. baileyana extracts respectively. Similarly, MIC values of 134 and 53 μg/mL were determined for the aqueous and methanolic E. major extracts respectively. The methanolic wattle seed extract, aqueous and methanolic lemon aspen extracts, aqueous native thyme extract, methanolic river mint extract and the methanolic native basil extract were similarly potent growth inhibitors, with MIC values ≤1000 μg/mL. Several other extracts (methanolic native tamarind, bush tomato, desert lime, native thyme, native sage and the T. stipitata leaf extracts, as well as the aqueous river mint, native basil, T. stipitata leaf extracts) displayed moderate growth inhibitory activity (MIC=1000-5000 μg/mL). All other extracts were either low potency S. pyogenes growth inhibitors or were devoid of inhibitory activity. The E. baileyana and E. major methanolic extracts, as well as the E. baileyana aqueous extract induced significant mortality in the Artemia fransiscana bioassay, with LC50 values substantially <1000 μg/mL. All other extracts were nontoxic, with LC50 values >1000 μg/mL. Conclusion: The potent growth inhibitory bioactivity of the Eucalyptus spp., lemon aspen, wattle seed, native basil and river mint extracts against S. pyogenes demonstrates their potential for the treatment and prevention of S. pyogenes induced disease. However, the toxicity of the Eucalyptus spp. extracts may limit their use to topical treatments for pharyngitis and impetigo. As the lemon aspen, wattle seed, native basil and river mint extracts were nontoxic, they may also have wider uses in treating systemic illnesses such as rheumatic fever, rheumatic heart disease and cellulitis.

Journal Title

Pharmacognosy Communications

Conference Title
Book Title
Edition
Volume

6

Issue

3

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© The Author(s) 2016. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International (CC BY-NC-ND 4.0) License (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.

Item Access Status
Note
Access the data
Related item(s)
Subject

Plant Biology

Pharmacology and Pharmaceutical Sciences

Persistent link to this record
Citation

Jay Lee, C; Henry Wright, M; Jean Arnold, MS; Carlson Greene, A; Edwin Cock, I, Inhibition of Streptococcus pyogenes growth by native Australian plants: New approaches towards the management of impetigo, pharyngitis and rheumatic heart disease, Pharmacognosy Communications, 6 (3), pp. 164-173

Collections